Cost-effectiveness Analyses for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK

Not yet recruitingOBSERVATIONAL
Enrollment

8,000

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Kidney Injury
Interventions
OTHER

RenalGuard Therapy

The RenalGuard Therapy® is comprised of a console, a single-use sterile IV infusion set, urine collection set and a cart. The console is a microcontroller device that has a means for measuring urine output and automatically controls the hydration infusion pump based on the measured urine output and clinician settings. The system is designed for infusion of hydration solutions only. The patient is connected to the console by the IV Infusion set connected to the patient's peripheral IV cannula and the urine collection set connected to the patient's indwelling Foley urinary catheter. The console continuously monitors urine production by measuring the weight of urine in the collection set, converts the urine weight to volume and then, automatically infuses the pre-set volume of hydration fluid to compensate for this output.

Trial Locations (1)

WV10 0QP

New Cross Hospital, Wolverhampton

All Listed Sponsors
lead

The Royal Wolverhampton Hospitals NHS Trust

OTHER_GOV

NCT07108634 - Cost-effectiveness Analyses for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK | Biotech Hunter | Biotech Hunter